US5160313A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for preparing tissue for transplantation
Assignee: Artivion Inc
•
Filing: 1991-05-14
•
Granted: 1992-11-03
•
Expires: 2011-05-14
Abstract
Abstract A method is disclosed for preparing a transplantable tissue which has been cryopreserved with an intracellular cryoprotectant and then thawed. After thawing, the tissue is treated with a diluent (or eluent) solution to reduce the level of cryoprotectant in the cells to a substantially non-toxic level. This is conducted using a single dilution step. Cryoprotectants which are removable in this manner include dimethylsulfoxide, glycerol, propanediol and other compounds which penetrate the cells. The dilution step does not require end point titration and can be conducted over a time period greater than about 5 minutes.
Inventors
- 👤 John F. Carpenter
- 👤 Kelvin G. M. Brockbank
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:28
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/3683; A61L27/3687; A01; A01N; A01N1/00; A01N1/10; A01N1/12; A01N1/122; A01N1/125; A01N1/16; Y; Y10; Y10S; Y10S128/00; Y10S128/27; Y10S623/00; Y10S623/901
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
44 words
In a process for treating a transplantable tissue which has been cryopreserved with an intracellular cryoprotectant and thawed prior to transplantation, the improvement comprising eluting the intracellular cryoprotectant to a substantially non-toxic concentration with a solution in only a single step prior to transplantation.
Claim 2
Dependent Claim
44 words
In a process for treating a transplantable tissue which has been cryopreserved with an intracellular cryoprotectant and thawed prior to transplantation, the improvement comprising eluting the intracellular cryoprotectant to a substantially non-toxic concentration with a solution in only a single step prior to transplantation.
Claim 3
Dependent Claim
15 words
The process of claim 1 wherein the solution is comprised of a balanced salt solution.
Claim 4
Dependent Claim
14 words
The process of claim 2 wherein the solution is comprised of lactated Ringers solution.
Claim 5
Dependent Claim
13 words
The process of claim 1, 2 or 3 wherein the solution is hyperosmotic.
Claim 6
Dependent Claim
16 words
The process of claim 2 wherein the solution is further comprised of a substantially impermeant solute.
Claim 7
Dependent Claim
14 words
The process of claim 5 wherein the substantially impermeant solute is comprised of dextrose.
Claim 8
Dependent Claim
21 words
The process of claim 3 wherein the cryoprotected transplantable tissue has a final cryoprotectant concentration of about 0.25M to about 1M.
Claim 9
Dependent Claim
11 words
The process of claim 7 wherein the intracellular cryoprotectant is dimethylsulfoxide.
Claim 10
Dependent Claim
25 words
The process of claim 3 wherein the transplantable tissue is immersed in the solution at a temperature of about 0° C. to about 38° C.
Claim 11
Dependent Claim
14 words
The process of claim 1 wherein the transplantable tissue is cardiovascular or musculoskeletal tissue.
Claim 12
Dependent Claim
18 words
The process of claim 10 wherein the transplantable tissue is a vein, artery, heart valve, ligament or tendon.
Claim 13
Dependent Claim
13 words
The process of claim 11 wherein the transplantable tissue is a heart valve.
Claim 14
Dependent Claim
14 words
The process of claim 12 wherein the heart valve is an allograft heart valve.
Claim 15
Dependent Claim
51 words
A process for reducing the concentration of intracellular cryoprotectant in a cryopreserved and thawed transplantable tissue comprising: treating the tissue with a solution after thawing to cause elution of the cryoprotectant out of the tissue in only a single step until the cryoprotectant concentration is from about 0.25M to about 1M.
Claim 16
Dependent Claim
51 words
A process for reducing the concentration of intracellular cryoprotectant in a cryopreserved and thawed transplantable tissue comprising: treating the tissue with a solution after thawing to cause elution of the cryoprotectant out of the tissue in only a single step until the cryoprotectant concentration is from about 0.25M to about 1M.
Claim 17
Dependent Claim
16 words
The process of claim 14 wherein the solution is further comprised of a substantially impermeant solute.
Claim 18
Dependent Claim
14 words
The process of claim 14 wherein the solution is comprised of lactated Ringers solution.
Claim 19
Dependent Claim
14 words
The process of claim 15 wherein the substantially impermeant solute is comprised of dextrose.
Claim 20
Dependent Claim
67 words
In a process for treating a transplantable tissue prior to transplantation which has been cryopreserved with an intracellular cryoprotectant and thawed, the improvement comprising diluting the intracellular cryoprotectant with a solution comprised of lactated Ringers solution and 5% dextrose in only a single elution step prior to transplantation without substantially reducing the viability of the transplantable tissue upon transplantation into a patient in need of such treatment.
Claim 21
Dependent Claim
67 words
In a process for treating a transplantable tissue prior to transplantation which has been cryopreserved with an intracellular cryoprotectant and thawed, the improvement comprising diluting the intracellular cryoprotectant with a solution comprised of lactated Ringers solution and 5% dextrose in only a single elution step prior to transplantation without substantially reducing the viability of the transplantable tissue upon transplantation into a patient in need of such treatment.
Claim 22
Dependent Claim
14 words
The process of claim 18 wherein the transplantable tissue is cardiovascular or musculosketal tissue.
Claim 23
Dependent Claim
18 words
The process of claim 19 wherein the transplantable tissue is a vein, artery, heart valve, ligament or tendon.
Claim 24
Dependent Claim
13 words
The process of claim 20 wherein the transplantable tissue is a heart valve.
Claim 25
Dependent Claim
14 words
The process of claim 21 wherein the heart valve is an allograft heart valve.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-11-03 | 1996-05-04 | 1996-11-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-11-03 | 2000-05-04 | 2000-11-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-11-03 | 2004-05-04 | 2004-11-03 | $7700.00 | Window Closed / Lapsed |